Esperion Therapeutics, Inc. 8-K

What Happened
Esperion Therapeutics, Inc. (ESPR) filed a Form 8-K on January 12, 2026 disclosing a press release and management presentation issued January 11, 2026 that announced preliminary 2025 results and provided financial guidance for the fiscal year ending December 31, 2026. Management’s guidance for 2026 expects: R&D expenses of $40–$50 million, selling, general & administrative (SG&A) expenses of $170–$195 million, and total operating expenses of $210–$245 million. The filing was signed by President and CEO Sheldon L. Koenig.

Key Details

• The guidance ranges are management’s current expectations for fiscal year 2026 (year ending Dec 31, 2026).
• Research & development (R&D) expenses: $40 million to $50 million.
• Selling, general & administrative (SG&A) expenses: $170 million to $195 million.
• Total operating expenses: $210 million to $245 million.
• The company issued a press release and slides (dated Jan 11, 2026) accompanying the presentation.

Why It Matters
This filing gives investors specific guidance on Esperion’s expected 2026 cost structure, which is key for modeling cash burn, runway and funding needs. The R&D and SG&A ranges drive the company’s operating expense outlook; comparing these figures with cash on hand and any disclosed revenue or financing can help assess whether Esperion may need additional capital in 2026. The filing does not disclose detailed revenue or full-year 2025 financials in the 8-K excerpt beyond noting preliminary 2025 results were announced.